The Importance of Lung Cancer Screening
Date: Wednesday, June 22, 2022; 3-4pm ET
The Importance of Lung Cancer Screening
Lung cancer is the main cause of cancer deaths in the United States. Given the maturity and strength of evidence supporting its impact, implementation of lung cancer management programs should be a priority in early detection efforts. This program will discuss the expanded USPSTF recommendations, changes in the reimbursement landscape, including the recent change in the Medicare National Coverage Determination. Speakers will discuss their own experiences with lung cancer screening and management, describing other modalities of early detection and the importance of a coordinated, multi-disciplinary approach. The program will conclude with a call to action for providing optimal care and driving early detection of lung cancer to save more lives.
This program was supported by a medical education grant from AstraZeneca.
• Primary care teams
• Practice managers
• Physician assistants
• Health plans
• Health systems
• Population health organizations
• Wellness organizations leveragers are federal, states and employers
Mary Barton, MD
Vice President, Performance Measurement
NCQA, Washington, DC
Mary Barton, MD oversees the development, use and maintenance of techniques NCQA uses to evaluate health care quality. She ensures the scientific integrity of NCQA measurement and research. She also leads NCQA in winning and executing health care quality measurement contracts for federal and state governments.
Prior to NCQA, Barton worked for the Agency for Healthcare Research and Quality (AHRQ), where she was the scientific director of the U.S. Preventive Services Task Force (USPSTF). She supported and provided oversight for the methodological, evidence review and recommendation-making work of the USPSTF.
Before joining AHRQ, Barton was an assistant professor at Harvard Medical School, where she performed clinical epidemiology and health services research related to cancer screening and prevention in terms of access, test performance and outcomes.
Barton trained in primary care internal medicine at Brigham and Women’s Hospital in Boston and completed a general medicine research fellowship at Harvard. She has a clinical interest in and has presented widely about the performance of the clinical breast examination. She is a member of the American College of Physicians and the Society of General Internal Medicine.
Heather Bittner Fagan, MD, MPH, FAAFP
Faculty and Associate Vice Chair for Research
Family & Community Medicine
ChristianaCare, Claymont, DE
Heather Bittner Fagan, MD, MPH, is a practicing family physician and researcher. Her research funding includes receiving the American Cancer Society’s prestigious Cancer Control Career Development Award and multiple grants from National Cancer Institute. She has provided leadership for development and implementation of ACCEL, Delaware’s Center for Translational Research, funded for the last 9 years by the National Institute of General Medical Science.
Dr. Fagan is a national thought leader. She is the Chair of Delaware’s Early Detection & Prevention Committee for Delaware’s Cancer Consortium and is medical director for Screening for Life, Delaware’s Cancer Screening Program for uninsured and underinsured individuals. She is an invited member of the American Cancer Society’s National Lung Cancer Roundtable, an appointed advisor for the American Cancer Society’s Lung Cancer Screening guidelines and an invited speaker to the National Academy of Science and Medicine on the role of primary care in reducing cancer disparities.
Dr Fagan is a successful collaborator with teams internal and external to ChristianaCare. Her current work includes a highly successful intervention to increase lung cancer screening in primary care practices (manuscript in process) and a new collaborative interventional study with four institutions to further the study of primary care practice interventions to improve lung cancer screening, to begin July 1, 2022
Elliot Servais, MD, FACS
Adult General Thoracic Surgery
Lahey Hospital and Medical Center, Burlington, MA
Dr. Servais is a general thoracic surgeon and Section Chief of Thoracic Surgery at Beth Israel Lahey Health, Lahey Hospital & Medical Center in Burlington, MA USA. He is Vice Chair for Quality in the Department of Surgery and the Director of the Robotic Thoracic Surgery program at Lahey. Dr. Servais is also Assistant Professor of Surgery at Tufts University School of Medicine. Dr. Servais trained in general surgery at New York-Presbyterian Hospital – Cornell Medical Center, thoracic oncology at Memorial Sloan-Kettering Cancer Center, and clinical thoracic surgery at Brigham & Women’s Hospital – Harvard Medical School.
Dr. Servais is board certified in both general and thoracic surgery. Dr. Servais has broad expertise in diseases of the chest and abdomen. Dr. Servais has particular expertise, research interest, and is well published in in lung cancer screening and the role for thoracic surgery in the multi-disciplinary approach to screening. Dr. Servais has additional expertise in the use of robotic surgery and other minimally invasive and advanced endoscopic techniques for lung and esophageal diseases. Dr. Servais holds positions on several international, national, and local society committees.
This live course grants 1.0 Other Continuing Education Unit (CEU) points for PCMH Certified Content Experts.
* Please note – You must attend the entire program to be eligible for total number of contact hours.
Disclosure of Relevant Financial Relationships
The National Committee for Quality Assurance (NCQA) endorses the Standards of the Accreditation Council for Continuing Medical Education which specify that sponsors of continuing medical education activities and presenters at and planners for these activities disclose any relevant financial relationships either party might have with commercial companies whose products or services are discussed in educational presentations.
For sponsors, relevant financial relationships include large research grants, institutional agreements for joint initiatives, substantial gifts, or other relationships that benefit the institution. For presenters or planning committee members, relevant financial relationships include the receipt of research grants from a commercial company, consultancies, honoraria, travel, or other benefits, or having a self-managed equity interest in a company; or having an immediate family member or partner with such a relationship.
Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
Relevant financial relationships exist with the following companies/organizations:
Heather Bittner Fagan: None
Elliot Servais: None
Additional Planning Committee Members:
Crissy Crittenden: None
This program was developed in part by NCQA staff.
This program received no commercial support.
- 1.00 Participation
- 1.00 PCMH CCE